Brief: TiumBio Submits CTA For Phase 1b Clinical Trial Of TU7710
26/03/2024 13:46
March 26 (Reuters) - TiumBio Co Ltd 321550.KQ :
* TIUMBIO SUBMITS CTA FOR PHASE 1B CLINICAL TRIAL OF TU7710,
A
LONG-ACTING RECOMBINANT ACTIVATED FACTOR VII, IN HEMOPHILIA A OR
B PATIENTS
Source text for Eikon: ID:nPn26hvlga
Further company coverage: 321550.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TiumBio Co
See all newsBrief: TiumBio And Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial Of 'Merigolix For Uterine Fibroids
Brief: TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab
Brief: TiumBio Submits CTA For Phase 1b Clinical Trial Of TU7710
Brief: Tiumbio To Initiate Phase 2 Trial Of Tu2218 For Cancer
Brief: Tiumbio And Hansoh Pharma Announce Clinical Trial Approval Of 'HS-10518/TU2670' From NMPA In China